Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCA033989 · 3 trials · 2 indications
Normalization of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug, including those leading to dose modification or discontinuation.
Number of participants with TEAEs leading to dose modification or discontinuation.
| Arm | Type | Description |
|---|---|---|
| INCA033989 | EXPERIMENTAL | Administered intravenous (IV) in accordance with the protocol-defined requirements. |
| Best Available Therapy (BAT) | EXPERIMENTAL | Best Available Therapy (BAT) will be selected by the investigator. |
| Part 1a Dose Escalation Cohort Disease Group A - with MF | EXPERIMENTAL | INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) will enroll in this group. |
| Part 1a Dose Escalation Cohort Disease Group A - with ET | EXPERIMENTAL | INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with essential thrombocythemia (ET) will enroll in this group. |
| Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R | EXPERIMENTAL | INCA033989 will be administered at a protocol defined starting regimen in 28- day cycles and will allow for the evaluation of INCA033989 in combination with ruxolitinib to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) exhibiting suboptimal response (SubOpt R) will enroll in this group. |
| Part 1b: Dose Expansion - with MF | EXPERIMENTAL | INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group. |
| Part 1b: Dose Expansion - with TGB-MF SubOpt R | EXPERIMENTAL | INCA033989 will be administered as an add-on therapy in combination with ruxolitinibat at the RDE(s) identified during Part 1a. Participants with treatment Group B (TGB) MF SubOpt R will enroll in this group. |
| Part 1b: Dose Expansion - with ET | EXPERIMENTAL | INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group. |
| Part 1c: Dose Expansion | EXPERIMENTAL | INCA033989 will be administered at the dose level found to exhibit an overall positive benefit/risk as monotherapy or as combination therapy with Ruxolitinib. Participants with myelofibrosis (MF) will enroll in this group. The participants enrolled in the monotherapy arm will be offered the option to crossover to combination therapy with ruxolitinib if a suboptimal response to monotherapy is observed after 12 weeks. |
| Name | Type | Description |
|---|---|---|
| INCA033989 | DRUG | Administered intravenous (IV) in accordance with the protocol-defined requirements. |
| Best Available Treatment | DRUG | Best Available Therapy (BAT) will be selected by the investigator. |
| Ruxolitinib | DRUG | Rux will be administered according to Prescribing Information/SmPC. |
Inclusion Criteria: * Confirmed diagnosis of high-risk ET. * Presence of mutCALR. * Prior treatment with at least 1 cytoreductive therapy. Exclusion Criteria: * Presence of any hematologic malignancy other than ET. * Major bleeding or thrombosis within the last 3 months prior to study enrollment....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 2 | PHASE3 | INCA033989, INCB057643, Ruxolitinib |
INCA033989 is an investigational oral small molecule being developed for essential thrombocythemia and other myeloproliferative neoplasms. It is designed for patients whose disease is driven by mutations in the calreticulin gene, and it is being studied both as a monotherapy and in combination with ruxolitinib.
INCA033989 targets mutant calreticulin, known as mutCALR, a protein target. The drug is a small molecule directed at this mutated form of the calreticulin protein, which is the biomarker used to select patients for its clinical trials in myeloproliferative neoplasms.
INCA033989 is being developed by Incyte Corporation, which trades on Nasdaq under the ticker INCY. Incyte is sponsoring the clinical program, which includes a Phase 3 study in essential thrombocythemia and earlier-stage studies in myeloproliferative neoplasms.
INCA033989 is in Phase 3 development. The lead study is a randomized, controlled Phase 3 trial comparing INCA033989 with best available therapy in essential thrombocythemia. INCA033989 has received Breakthrough Therapy designation from the FDA and remains investigational.
INCA033989 is being evaluated in three registered studies. NCT07623200 is the Phase 3 trial versus best available therapy in essential thrombocythemia, enrolling 426 patients across North America, Europe, Asia and Australia. NCT06034002 and NCT05936359 are Phase 1 studies in myeloproliferative neoplasms testing monotherapy and combination with ruxolitinib.
No, INCA033989 is not approved. It is an investigational drug still in clinical development, currently in Phase 3 testing for essential thrombocythemia. The FDA has granted it Breakthrough Therapy designation, a status that supports and expedites development but does not constitute marketing approval.